Современный подход к фармакотерапии хронической инсомнии в детском возрасте
- Авторы: Тадтаева З.Г.1, Галустян А.Н.1, Кривошеин А.Е.1, Русановский В.В.1, Акимов А.А.1, Сардарян И.С.1, Курицына Н.А.1
-
Учреждения:
- Санкт-Петербургский педиатрический медицинский университет
- Выпуск: Том 22, № 2 (2024)
- Страницы: 205-217
- Раздел: Клиническая фармакология
- URL: https://journals.rcsi.science/RCF/article/view/263150
- DOI: https://doi.org/10.17816/RCF624874
- ID: 263150
Цитировать
Аннотация
Инсомния — широко распространенная проблема среди педиатрического населения. Распространенность инсомнии в детском возрасте варьирует от 5 до 50 %. Отсутствие адекватной терапии может приводить к хронизации заболевания, нарушению когнитивных и двигательных функций ребенка, а в долгосрочной перспективе — к развитию сердечно-сосудистых и метаболических заболеваний, сахарного диабета, желудочно-кишечных и психических расстройств. Таким образом, своевременное выявление и лечение детской бессонницы имеет важное значение. Цель работы — обобщить и систематизировать актуальную информацию о современном подходе к фармакотерапии хронической инсомнии в детском возрасте. Проведен анализ современных и зарубежных публикаций, рандомизированных контролируемых исследований за последние 10 лет. Лечение хронической инсомнии включает нефармакологические и фармакологические подходы. Поведенческие стратегии рекомендованы в качестве первой линии терапии детской инсомнии. Наличие различных фармакологических групп препаратов позволяет осуществлять персонализированный подход к лечению. Применение off-label-препаратов требует обоснованного назначения. Отсутствие широкомасштабных клинических исследований по эффективности, переносимости, дозировании и профилю безопасности препаратов диктует необходимость дальнейших исследований для лучшего понимания рисков (негативных побочных эффектов) и преимуществ применения медикаментозных средств при нарушениях сна у детей.
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Зара Григорьевна Тадтаева
Санкт-Петербургский педиатрический медицинский университет
Автор, ответственный за переписку.
Email: tadtaeva2003@mail.ru
ORCID iD: 0000-0002-5809-1457
SPIN-код: 6086-0169
Scopus Author ID: 57222536682
д-р мед. наук
Россия, Санкт-ПетербургАнна Николаевна Галустян
Санкт-Петербургский педиатрический медицинский университет
Email: dr.galustyan@gmail.com
ORCID iD: 0000-0001-9679-632X
SPIN-код: 3303-7650
канд. мед. наук, доцент
Россия, Санкт-ПетербургАлександр Евгеньевич Кривошеин
Санкт-Петербургский педиатрический медицинский университет
Email: krivoshein20@mail.ru
ORCID iD: 0000-0002-4714-1180
Россия, Санкт-Петербург
Владимир Васильевич Русановский
Санкт-Петербургский педиатрический медицинский университет
Email: rusvv2058@mail.ru
ORCID iD: 0000-0002-0432-7946
SPIN-код: 7010-4530
Scopus Author ID: 57444102200
д-р мед. наук
Россия, Санкт-ПетербургАлександр Анатольевич Акимов
Санкт-Петербургский педиатрический медицинский университет
Email: laboremus_07@mail.ru
SPIN-код: 4176-2536
канд. мед. наук
Россия, Санкт-ПетербургИван Суренович Сардарян
Санкт-Петербургский педиатрический медицинский университет
Email: ivan.sardaryan@gmail.com
ORCID iD: 0000-0002-1528-411X
SPIN-код: 9522-9761
канд. мед. наук
Россия, Санкт-ПетербургНаталья Андреевна Курицына
Санкт-Петербургский педиатрический медицинский университет
Email: bely25193@yandex.ru
ORCID iD: 0000-0002-0200-5097
SPIN-код: 4361-7365
канд. биол. наук
Россия, Санкт-ПетербургСписок литературы
- Al Lihabi A. A literature review of sleep problems and neurodevelopment disorders. Front Psychiatry. 2023;14:1122344. doi: 10.3389/fpsyt.2023.1122344
- Coogan AN, Baird AL, Popa-Wagner A, Thome J. Circadian rhythms and attention defcit hyperactivity disorder: the what, the when and the why. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;67:74–81. doi: 10.1016/j.pnpbp.2016.01.006
- Chokroverty S. Overview of sleep and sleep disorders. Indian J Med Res. 2010;131:126–140.
- Ogundele MO, Yemula C. Management of sleep disorders among children and adolescents with neurodevelopmental disorders: A practical guide for clinicians. World J Clin Pediatr. 2022;11(3): 239–252. doi: 10.5409/wjcp.v11.i3.239
- Gregory AM, Sadeh A. Sleep, emotional and behavioral difficulties in children and adolescents. Sleep Med Rev. 2012;16(2):129–136. doi: 10.1016/j.smrv.2011.03.007
- Irwin MR. Why sleep is important for health: A psychoneuroimmunology perspective. Annu Rev Psychol. 2015;66:143–172. doi: 10.1146/annurev-psych-010213-115205
- Karabanova OА. In search of an optimal parenting style. National Psychological Journal. 2019;3(3):71–79. EDN: WFULTG doi: 10.11621/npj.2019.0308
- Poluektov MG. Sleep disorders in childhood: causes and modern therapy. Effective pharmacotherapy. 2012;(1):32–39. EDN: SLUCSZ (In Russ.)
- Kharlamov DA, Kremenchugskaya MR, Trifonova OE. Polysomnography in the sleep disorders diagnostics in children. Russian Bulletin of Perinatology and Pediatrics. 2008;53(5):52–58. EDN: JUAQSV
- American Academy of Sleep Medicine. International classification of sleep disorders. 3rded. (ICSD-3). Darien: American Academy of Sleep Medicine; 2014.
- Maski K, Owens JF. Insomnia, parasomnias, and narcolepsy in children clinical features, diagnosis, and management. Lancet Neurol. 2016;15(11):1170–1181. doi: 10.1016/S1474-4422(16)30204-6
- Korabelnikova EA. Treatment and prevention of insomnia in infants and young children. Russian Journal of Psychiatry. 2012;(3):62–67. EDN: PBYNTH
- BruniО, Angriman M, Calisti F, et al. Practitioner Review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities. J Child Psychol Psychiatry. 2018;59(5): 489–508. doi: 10.1111/jcpp.12812
- Zhou ES, Owens J. Behavioral treatments for pediatric insomnia. Curr Sleep Med Rep. 2016;2:127–135. doi: 10.1007/s40675-016-0053-0
- Kang EK, Kim SS. Behavioral insomnia in infants and young children. Clin Exp Pediatr. 2021;64(3):111–116. doi: 10.3345/cep.2020.00052
- Pchelina PV, Poluektov MG. How to treat insomnia of early childhood. Effective pharmacotherapy. 2016;(19):52–58. EDN: WIEOWT
- Narasimhan U, Anitha FS, Battula M Jr. Specific learning disability unmasked by psychophysiological insomnia. Cureus. 2020;12(3): e7480. doi: 10.7759/cureus.7480
- Ophof D, Slaats MA, Boudewyns A, et al. Sleep disorders during childhood: a practical review. Eur J Pediatr. 2018;177(5):641–648. doi: 10.1007/s00431-018-3116-z
- Kaczor M, Skalski M. Treatment of behavioral sleep problems in children and adolescents — literature review. Psychiatr Pol. 2016;50(3):571–584. doi: 10.12740/PP/41294
- Neubauer DN, Pandi-Perumal SR, Spence DW, et al. Pharmacotherapy of Insomnia. J Cent Nerv Syst Dis. 2018;10:1179573518770672. doi: 10.1177/1179573518770672
- Okovityi SV, Titovich IA. Pharmacotherapy treatment principles for insomnia. Medical council. 2018;(6):26–32. EDN: YVEXRJ doi: 10.21518/2079-701X-2018-6-26-32
- Monti JM. The neurotransmitters of sleep and wake, a physiological reviews series. Sleep Med Rev. 2013;17(4):313–315. doi: 10.1016/j.smrv.2013.02.004
- Pelayo R, Dubic M. Pediatric sleep pharmacology. Semin Pediatr Neurol. 2008;15(2):79–90. doi: 10.1016/j.spen.2008.03.004
- Monczor F, Fernandez N. Current knowledge and perspectives on histamine H1 and H2 receptor pharmacology: functional selectivity, receptor crosstalk, and repositioning of classic histaminergic ligands. Mol Pharmacol. 2016;90(5):640–648. doi: 10.1124/mol.116.105981
- Owens JA, Babcock D, Blumer J, et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches. A consensus meeting summary. J Clin Sleep Med. 2005;1(1):49–59. doi: 10.5664/jcsm.26297
- Romanov DV, Iuzbashian PG. Acute insomnia: experience of treatment with doxylamine. Medical Council. 2020;(21):267–273. EDN: YZBJOA doi: 10.21518/2079-701X-2020-21-267-273
- Samanta S. Physiological and pharmacological perspectives of melatonin. Arch Physiol Biochem. 2022;128(5):1346–1367. doi: 10.1080/13813455.2020.1770799
- Eckerberg B, Lowden A, Nagai R, Åkerstedt T. Melatonin treatment effects on adolescent students’ sleep timing and sleepiness in a placebo-controlled crossover study. Chronobiol Int. 2012;29(9): 1239–1248. doi: 10.3109/07420528.2012.719962;
- Van Maanen A, Meijer AM, Smits MG, et al. Effects of melatonin and bright light treatment in childhood chronic sleep onset insomnia with late melatonin onset: a randomized controlled study. Sleep. 2017;40(2):zsw038. doi: 10.1093/sleep/zsw038
- Kryger MH, Roth T, Goldstein CA. Kryger’s principles and practice of sleep medicine. Elsevier Health Sciences; 2021. 2240 p.
- Wagner ML, Walters AS, Fisher BC. Symptoms of attention-deficit/hyperactivity disorder in adults with restless legs syndrome. Sleep. 2004;27(8):1499–1504. doi: 10.1093/sleep/27.8.1499
- Himelfarb M, Shatkin JP. Pediatric insomnia. Child Adolesc Psychiatr Clin N Am. 2021;30(1):117–129. doi: 10.1016/j.chc.2020.08.004
- Zawilska JB, Skene DJ, Arendt J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep. 2009;61(3):383–410. doi: 10.1016/S1734-1140(09)70081-7
- Andersen IM, Kaczmarska JA, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. 2008;23(5):482–485. doi: 10.1177/0883073807309783
- Carr R, Wasdell MB, Hamilton D, et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. J Pineal Res. 2007;43(4):351–359. doi: 10.1111/j.1600-079X.2007.00485.x
- Lin G-J, Huang S-H, Chen S-J, et al. Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. Int J Mol Sci. 2013;14(6):11742–11766. doi: 10.3390/ijms140611742
- Chua HM, Hauet Richer N, Swedrowska M, et al. Dissolution of intact, divided and crushed circadin tablets: prolonged vs. immediate release of melatonin. Pharmaceutics. 2016;8(1):2. doi: 10.3390/pharmaceutics8010002
- Barylnik YB, Filippova NV, Treiber LV. Modern approaches to synchronisation of circadian rhythms in depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(11):124–128. EDN: RILCEV (In Russ.)
- grls.rosminzdrav.ru [Internet]. State register of medicines. Available from: http://grls.rosminzdrav.ru (In Russ.)
- Pushkarev DF. Alimemazine in psychiatric practice and general medicine (literature review). Mental Disorders in General Medicine. 2013;(1):56–61. EDN: QCALFZ (In Russ.)
- Ramchandani P, Wiggs L, Webb V, Stores G. A systematic review of treatments for settling problems and night waking in young children. BMJ. 2000;320(7229):209–213. doi: 10.1136/bmj.320.7229.209
- Ingrassia A, Turk J. The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders. Eur Child Adolesc Psychiatry. 2005;14:34–40. doi: 10.1007/s00787-005-0424-4
- Romanov DV, Samsonova MD, Iuzbashian PG. Treatment of mental disorders caused or triggered by somatic and neurological diseases with the use of the multimodal antidepressant trazodone. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123 (4–2):81–89. EDN: TRIOHE doi: 10.17116/jnevro202312304281
- Wichniak A, Wierzbicka A, Jernajczyk W. Sleep and antidepressant treatment. Curr Pharm Des. 2012;18(36):5802–5817. doi: 10.2174/138161212803523608
- Belli A, Breda M, Di Maggio C, et al. Children with neurodevelopmental disorders: how do they sleep? // Curr Opin Psychiatry. 2022:1(5):345–351. doi: 10.1097/YCO.0000000000000790. Epub 2022 Feb 15. PMID: 35165244.
- Khachatrian LG, Pogorelova MS, Geppe NA, et al. The problem of insomnia in infant/young children: issues of diagnosis and treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(7–2): 25–32. EDN: CFBLIZ doi: 10.17116/jnevro201911907225
- Poluéktov MG, Tsenteradze SL. A contemporary conception of insomnia syndrome and its treatments in view of international classification of sleep disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(11):92–97. EDN: TGMIDL
- Raggi A, Mogavero MP, DelRosso LM, Ferri R. Clonazepam for the management of sleep disorders. Neurol Sci. 2023;44(1):115–128. doi: 10.1007/s10072-022-06397-x
- Relia S, Ekambaram V. Pharmacological approach to sleep disturbances in autism spectrum disorders with psychiatric comorbidities: A Literature review. Med Sci. 2018;6(4):95. doi: 10.3390/medsci6040095
- Owens JA, Rosen CL, Mindell JA, Kirchner HL. Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey. Sleep Med. 2010;11(7):692–700. doi: 10.1016/j.sleep.2009.11.015
- Hollway JA, Aman MG. Pharmacological treatment of sleep disturbance in developmental disabilities: a review of the literature. Res Dev Disabil. 2011;32(3):939–962. doi: 10.1016/j.ridd.2010.12.035
- Robinson AA, Malow BA. Gabapentin shows promise in treating refractory insomnia in children. J Child Neurol. 2013;28(12): 1618–1621. doi: 10.1177/0883073812463069
- Meltzer LJ, Mindell JA, Owens JA, Byars KC. Use of sleep medications in hospitalized pediatric patients. Pediatrics. 2007;119(6): 1047–1055. doi: 10.1542/peds.2006-2773
- Meolie AL, Rosen C, Kristo D, et al. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin Sleep Med. 2005;1(2):173–187. doi: 10.5664/jcsm.26314
- Giambersio D, Marzulli L, Margari L, et al. Correlations between sleep features and iron status in children with neurodevelopmental disorders: A cross-sectional study. J Clin Med. 2023;12(15):4949. doi: 10.3390/jcm12154949
- Torres-Vega A, Pliego-Rivero BF, Otero-Ojeda GA, et al. Limbic system pathologies associated with deficiencies and excesses of the trace elements iron, zinc, copper, and selenium. Nutr Rev. 2012;70(12):679–692. doi: 10.1111/j.1753-4887.2012.00521.x
- Maltsev SV. Modern data on vitamin D — metabolism, role in the organism, and features of application in a doctor’s practice. Practicalmedicine. 2020;18(4):8–22. EDN: YTJJFL doi: 10.32000/2072-1757-2020-4-8-22
- Romano F, Muscogiuri G, Di Benedetto E, et al. Vitamin D and sleep regulation: Is there a role for vitamin D? Curr Pharm Des. 2020;26(21):2492–2496. doi: 10.2174/1381612826666200310145935
- Al-Shawwa B, Ehsan Z, Ingram DG. Vitamin D and sleep in children. J Clin Sleep Med. 2020;16(7):1119–1123. doi: 10.5664/jcsm.8440
- Patrick RP, Ames BN. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: Relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. FASEB J. 2015;29(6):2207–2222. doi: 10.1096/fj.14-268342
- Abboud M. Vitamin D supplementation and sleep: A systematic review and meta-analysis of intervention studies. Nutrients. 2022;14(5):1076. doi: 10.3390/nu14051076
